Skip to main content
. 2021 Apr 4;13(1):1890411. doi: 10.1080/19420862.2021.1890411

Figure 2.

Figure 2.

TNB-486 is a fully human bispecific antibody engaging CD19 and CD3 (a) TNB-486 was constructed using knobs-into-holes technology. The format of the antibody is depicted. (b) Cell binding dose curves of TNB-486 on three CD19+ B cell lines Daudi, Raji and Nalm-6, and one CD19- cell line, K562 is shown. (c) Cell surface affinity of TNB-486 to CD19 expressed on Nalm-6 cells was determined by Scatchard analysis